CAR-NK cells with multi-specific molecules composed of stabilized CD16 and/or other activating receptors (e.g., NKG2D, DNAM-1/CD226, NKp46/NCR1, NKp44/NCR2, and NKp30/NCR3), scFvs for tumor antigens ...

By connecting with its tumor-associated overexpression ligands, such as MICA, MICB, and ULBPs, NKG2D, an activating NK cell receptor can modulate the cytotoxic capability of NK cells against ...

The bispecifics are differentiated through their targeting of NKp46 to engage NK cells, rather than the CD16 and NKG2D receptors targeted by other bispecifics. Importantly, NKp46 expression is ...

CAR-NK cells containing multi-specific molecules made up of relatively stable CD16 and other activating receptors (e.g., NKG2D, DNAM-1/CD226, NKp46/NCR1, NKp44/NCR2, and NKp30/NCR3), scFvs for ...

Unlike NK cells, γ6 T cells recognize these antigens through both the natural killer group 2D (NKG2D) receptor and the γ6 T cell receptor, allowing for an overlap in targeting. Activated γ6 T ...